Back to search results

NaviFUS System with Bevacizumab for Recurrent Glioblastoma

This study is looking at the safety and early effectiveness of combining the NaviFUS System with Bevacizumab (Avastin) for people with recurrent glioblastoma (a type of brain tumor). The NaviFUS System uses focused ultrasound and microbubbles (tiny bubbles given intravenously) to temporarily open the blood-brain barrier, which might help Bevacizumab reach the tumor better. We are looking for adults aged 18 or older who have glioblastoma that has come back after previous treatments. The main goal is to see how safe this combination treatment is by tracking any side effects. There are 10 people planned to join this study. The current status of the study is unclear.

Study design
This is an interventional study with a planned enrollment of 10 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety will be assessed through study completion, up to 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07274787

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

Not Yet Recruiting
NAAges 18+InterventionalTreatment
University of Cincinnati
~10 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:NaviFUS SystemLumasonBevacizumab

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety -assessed using -Device-related Adverse Events (AEs) reported
Measured over Through study completion, up to 24 weeks

Conditions

GBM

Explore related trials

Glioblastoma

Where it's being run

1 sites across 1 states
Ohio1

Who to contact

UCCC Clinical Trials Office
[email protected]
513-584-7698
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

1\) Previous treatment with an inhibitor of vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR), including bevacizumab.

What this trial measures

  • Safety -assessed using -Device-related Adverse Events (AEs) reportedThrough study completion, up to 24 weeks

    The primary objective of this clinical investigation is to evaluate the safety of BEV combined with the NaviFUS System for the treatment of patients with recurrent GBM. Safety will be assessed using the following methods: Device-related Adverse Events (AEs) reported \[Time Frame: Through study completion, up to 24 weeks\].